Singapore markets closed

23andMe Holding Co. (ME)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.85-0.29 (-3.17%)
At close: 04:00PM EST
8.80 -0.05 (-0.56%)
Pre-market: 07:00AM EST
Full screen
Trade prices are not sourced from all markets
Previous close9.14
Open9.15
Bid0.00 x 800
Ask0.00 x 4000
Day's range8.71 - 9.24
52-week range7.01 - 18.16
Volume1,990,793
Avg. volume2,574,192
Market cap3.872B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.21
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est13.50
  • Motley Fool

    Why 23andMe Stock Crashed 10% Today

    Shares of genetic data miner 23andMe Holding (NASDAQ: ME) had a good week last week, surging more than 13% in response to a positive second-quarter 2022 earnings report Thursday. Things got even worse today, when investors responded to a downgrade of 23andMe stock by a Citigroup analyst -- by selling off the stock by 10.1% (as of 11:30 a.m. EST). In my own note on the company last week, I pointed out that sales growth at 23andMe was a weak 7% in Q2, down steeply from Q1's 23% growth pace.

  • Motley Fool

    Why 23andMe Stock Scored an 11% Gain Today

    23andMe lost a lot less money than feared today -- so why is it sticking with a prediction for a full-sized loss for the year?

  • Motley Fool

    Why 23andMe Rocketed 27.9% Higher in October

    Shares of 23andMe (NASDAQ: ME) jumped 27.9% in October, according to data from S&P Global Market Intelligence. The consumer genetics and pharmaceutical research company announced an acquisition of the telehealth platform Lemonaid Health for $400 million last month, which is the main news that drove up the stock price. 23andMe is the company behind the popular genetic testing kits where consumers can learn about their ancestry background and genetic health.